BioWorld Asia

Nov. 7, 2007

Ark Raising $73M To Advance New Gene Therapy Products

Overlooked VEGF Relation May Have Fewer Side Effects

GPC Wins Spectrum Dispute; Wider Uncertainty Continues

GPC Biotech AG emerged successfully from its legal dispute with partner Spectrum Pharmaceuticals Inc., although the circumstances surrounding the case altered radically in the interim. (BioWorld International) Read More

Syntaxin Raises $33M To Boost Its Pipeline

Other News To Note

EMA Reveals Reasoning Behind Product Rejection

Nitec Gains Rights To Paz's Tarenflurbil For Inflammation

GAO: FDA Must Get Tougher On Foreign Facility Inspections

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...